apellis pharmaceuticals inc apls reported a second quarter q2 eps loss of 102 beating the consensus of 135 sales came in at 95 million up from 163 million a year ago beating the consensus of 7172 million the sales included 223 million of the us net product revenue of empaveli and 673 million of the us net product revenue of syfovre cash and cash equivalents of 6163 million as of june 30 2023 expected cash runway into q1 2025 over 31000 commercial vials and nearly 11000 samples of syfovre were delivered to physician practices in the second quarter the total number of vials delivered since launch through july 29 is over 68000 last week the company provided an update on its review of rare events of retinal vasculitis reported in realworld treatment with syfovre pegcetacoplan injection for geographic atrophy ga secondary to agerelated macular degeneration amd apellis has been conducting a thorough evaluation following these reported events and noted no changes in the product formulation between phase 3 trials and commercial supply based on this review there is no indication that drug product or manufacturing issues contributed to these events and there were no new safety findings in the clinical trials upon secondary review no quality issues and no contaminants were discovered no single manufacturing lot was implicated no indication of drugrelated immunogenicity was observed in the trial data zero events of retinal vasculitis were reported by investigators or identified by an independent reading center in phase 3 trials since syfovres launch apellis has had seven confirmed events of retinal vasculitis 4 occlusive three nonocclusive additionally apellis announced data from the gale extension study following 30 months of continuous treatment with syfovre syfovre reduced nonsubfoveal ga lesion growth by up to 45 between months 2430 compared to the projected sham in the gale longterm extension study price action apls shares are down more than 102 today hovering at around 2875 on the last check monday